Elemene plus standard therapy for newly diagnosed glioblastoma
Part of Cancer clinical trials.
This trial tests whether adding a medicine called elemene to the standard treatment (the Stupp protocol) helps people with newly diagnosed glioblastoma live longer or have better outcomes. It is for adults under 70 who have not yet had treatment for their brain tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be younger than 70 years old.
- You must have a newly diagnosed glioblastoma (a type of brain tumor) that has not been treated before.
- You need to be in generally good health, able to care for yourself, and have enough energy for daily activities.
- Your liver, kidneys, and blood counts must be within acceptable ranges (tests will be done to check).
- You must be willing to follow the treatment schedule and come to follow-up visits.
- You cannot be pregnant or breastfeeding, and you must not have serious infections or other major health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
This Phase 2 study tests whether adding metformin to standard radiation and temozolomide (chemo) can improve outcomes for people with newly diagnosed glioblastoma of a specific metabolic subtype. It aims to see if this combination is safer and more effective than standard treatment alone.
This trial tests whether adding an extended-release seizure medication (levetiracetam) to standard treatment helps people with a certain type of glioblastoma. It may improve outcomes by targeting tumors with low oxygen levels.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
Hear when a new Glioblastoma, IDH-wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.